



Press release

VALBIOTIS: 2019 financial communication calendar

La Rochelle, 22 March 2019 (7:35 AM CET) – **VALBIOTIS** (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today presents its 2019 financial communication calendar.

In 2019, the Company will meet investors, particularly individual shareholders by attending 3 events dedicated to retail investors, in Paris and Bordeaux (France).

- 25 March 2019: Investment Clubs and Individual Investors Federation meeting (Fédération des Investisseurs Individuels et des Clubs d'Investissement, F2IC), Paris
- 26 March 2019: Biotech AGORA meeting, Paris
- 4 April 2019: Market Solutions Forum ESN – CM-CIC, Paris
- 10 April 2019: Portzamparc Midcap Conference 2019, Paris
- 16 April 2019: Invest Securities Smallcap Event 2019, Paris
- 21 May 2019: General Meeting, to vote for annual financial statement, Paris
- 23 May 2019: Meeting with individual investors from French south-west region (by F2IC, Champeil and Boursier.com), Bordeaux (France)
- 10 September 2019: Portzamparc Biotech Seminar, Paris
- 14-15 October 2019: Invest Securities Large and Midcap Event, Paris
- 24 October 2019: Galien MedStartUp, New York
- 31 October 2019: Half-year Report

VALBIOTIS published its 2018 annual report on March 8th 2019. This document and an updated corporate presentation are available for download on the corporate website of the Company, at the following link: www.valbiotis.com/en/investors

ABOUT VALBIOTIS

VALBIOTIS is a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the healthcare sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The company is located at 3 sites in France – Périgny, La Rochelle (17) and Riom (63) – in addition to an American office in Boston (MA).

VALBIOTIS is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. VALBIOTIS has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

VALBIOTIS is PEA/SME eligible.

Find out more about VALBIOTIS :

www.valbiotis.com



VALBIOTIS
CORPORATE
COMMUNICATIONS
Carole ROCHER /
Marc DELAUNAY
+33 (0)5 46 28 62 58
medias@valbiotis.com

FINANCIAL
COMMUNICATIONS
ACTIFIN
Stéphane RUIZ
+33 (0)1 56 88 11 14
sruiz@actifin.fr

MEDIA RELATIONS
MADIS PHILEO
Guillaume DE CHAMISSO
+33 (0)6 85 91 32 56
guillaume.dechamisso@madisphileo.com

UNITED STATES
SOLEBURY TROUT
Rebecca JOHN / Patrick TILL
+1 646 378 2935
rjohn@troutgroup.com
ptill@troutgroup.com



Name: VALBIOTIS
ISIN code:
FR0013254851
Mnemonic code:
ALVAL



DISCLAIMER

This press release contains forward-looking statements concerning the objectives of VALBIOTIS. VALBIOTIS considers that these projections are based on information currently available by VALBIOTIS and on reasonable assumptions.

However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of VALBIOTIS filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number I.17-012 on April 5, 2017 as well as in its 2018 annual financial report filed with the French Financial Markets Authority on March 8, 2019. These documents are available on the Company's website (www.valbiotis.com).

VALBIOTIS declines all responsibility for updating or revising these forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, VALBIOTIS shares in any country.